List of Reclast drug patents
Reclast is owned by Novartis.
Reclast contains Zoledronic Acid.
Reclast has a total of 3 drug patents out of which 0 drug patents have expired.
Reclast was authorised for market use on 16 April, 2007.
Reclast is available in injectable;intravenous dosage forms.
Reclast can be used as treatment and prevention of postmenopausal or glucocorticoid-induced osteoporosis and treatment to increase bone mass in men with osteoporosis.
The generics of Reclast are possible to be released after 05 August, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8052987 | NOVARTIS | Method of administering bisphosphonates |
Oct, 2023
(8 months from now) | |
| US7932241 | NOVARTIS | Pharmaceutical products comprising bisphosphonates |
Feb, 2028
(5 years from now) | |
|
US7932241
(Pediatric) | NOVARTIS | Pharmaceutical products comprising bisphosphonates |
Aug, 2028
(5 years from now) | |
Drugs and Companies using ZOLEDRONIC ACID ingredient
Market Authorisation Date: 16 April, 2007
Treatment: Treatment and prevention of postmenopausal or glucocorticoid-induced osteoporosis and treatment to increase bone mass in men with osteoporosis
Dosage: INJECTABLE;INTRAVENOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic